Please use this identifier to cite or link to this item:
Title: The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.
Authors: Warrender-Sparkes, Matthew
Spelman, Tim
Izquierdo, Guillermo
Trojano, Maria
Lugaresi, Alessandra
Grand'Maison, François
Havrdova, Eva
Horakova, Dana
Boz, Cavit
Oreja-Guevara, Celia
Alroughani, Raed
Iuliano, Gerardo
Duquette, Pierre
Girard, Marc
Terzi, Murat
Hupperts, Raymond
Grammond, Pierre
Petersen, Thor
Fernandez-Bolaños, Ricardo
Fiol, Marcela
Pucci, Eugenio
Lechner-Scott, Jeannette
Verheul, Freek
Cristiano, Edgardo
Van Pesch, Vincent
Petkovska-Boskova, Tatjana
Moore, Fraser
Kister, Ilya
Bergamaschi, Roberto
Saladino, Maria Laura
Slee, Mark
Barnett, Michael
Amato, Maria Pia
Shaw, Cameron
Shuey, Neil
Young, Carolyn
Gray, Orla
Kappos, Ludwig
Butzkueven, Helmut
Kalincik, Tomas
Jokubaitis, Vilija
MSBase study group
Keywords: MSBase;Multiple sclerosis;disease-modifying therapy;fingolimod;medication persistence
metadata.dc.subject.mesh: Administration, Oral
Demyelinating Diseases
Drug Substitution
Fingolimod Hydrochloride
Immunosuppressive Agents
Kaplan-Meier Estimate
Medication Adherence
Middle Aged
Multiple Sclerosis, Relapsing-Remitting
Multivariate Analysis
Proportional Hazards Models
Prospective Studies
Risk Factors
Time Factors
Treatment Outcome
Issue Date: 21-Jul-2015
Abstract: We aimed to analyse the effect of the introduction of fingolimod, the first oral disease-modifying therapy, on treatment utilisation and persistence in an international cohort of patients with multiple sclerosis (MS). MSBASIS, a prospective, observational sub-study of the MSBase registry, collects demographic, clinical and paraclinical data on patients followed from MS onset (n=4718). We conducted a multivariable conditional risk set survival analysis to identify predictors of treatment discontinuation, and to assess if the introduction of fingolimod has altered treatment persistence. A total of 2640 patients commenced immunomodulatory therapy. Following the introduction of fingolimod, patients were more likely to discontinue all other treatments (hazard ratio 1.64, p Following the availability of fingolimod, patients were more likely to discontinue injectable treatments. Those who switched to fingolimod were more likely to do so for convenience. Persistence was improved on fingolimod compared to other medications.
metadata.dc.identifier.doi: 10.1177/1352458515594041
Appears in Collections:Producción 2020

Files in This Item:
There are no files associated with this item.

This item is protected by original copyright

Except where otherwise noted, Items on the Andalusian Health Repository site are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives License.